|
| Status |
Public on Apr 18, 2019 |
| Title |
Differential gene expression analysis in BRD4-PROTAC treated diffuse large B-cell lymphoma cell lines |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
We identified differential gene expression after treatment with BRD4-PROTAC ARV771 in two ABC-like diffuse large B-cella lymphoma cell lines. We have identified cluster of gene expression regulated after BRD4 inhibition which are criticaly important for DLBCL malignancy.
|
| |
|
| Overall design |
Two ABC-DLBCL cell lines were used to identify the changes in gene expression profile after BRD4-PROTAC (ARV771) treatment.
|
| |
|
| Contributor(s) |
Green M |
| Citation(s) |
31217338 |
| |
| Submission date |
Aug 30, 2018 |
| Last update date |
Jul 18, 2019 |
| Contact name |
Michael Green |
| E-mail(s) |
MGreen5@mdanderson.org
|
| Phone |
713-745-4244
|
| Organization name |
MD Anderson Cancer Center
|
| Street address |
7455 fannin street, SCR2.2026, Department of Lymphoma/Myeloma
|
| City |
HOUSTON |
| State/province |
TEXAS |
| ZIP/Postal code |
77054 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
|
| Samples (4)
|
|
| This SubSeries is part of SuperSeries: |
| GSE119477 |
Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in the activated B-cell subtype of diffuse large B-cell lymphoma. |
|
| Relations |
| BioProject |
PRJNA488595 |
| SRA |
SRP159156 |
Less...
More...